Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors reported to be useful for the treatment of cancer, infections, autoimmune diseases, cardiovascular diseases, inflammatory disorders and neurological conditions.